Search
for
Sort by
Research 30 of 1000+
- A Rare Case of Postmenopausal Hirsutism Associated With a Serous Cystadenofibroma of the Ovary
- Use of hair products in relation to ovarian cancer risk
- Case Study: Hereditary Cancer Genetic Testing in Unaffected Patients May Allow for Early Intervention and Aggressive Management
- S100A4/Nonmuscle Myosin IIA/p53 Axis Contributes to Aggressive Features in Ovarian High-Grade Serous Carcinoma
- Muir-torre syndrome in two families in Leicestershire, United Kingdom
- The evaluation and treatment of androgen excess
- 414 A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancer
- Winer's dilated pore, rare presentation in the external ear canal
- Ovarian Leydig cell tumor and postmenopausal hirsutism with signs of virilisation
- Histopathological Characteristics may not be Useful in the Differential Diagnosis Between Basal Cell Carcinoma and Benign Tumors of Cutaneous Appandages Originating from Hair Follicle
- Efeitos da finasterida sobre culturas de células epiteliais prostáticas normais e tumorais em diferentes sistemas in vitro
- Hirsutism causes and treatments.
- Postmenopausal hyperandrogenism
- MANAGEMENT OF ENDOCRINE DISEASE: Hyperandrogenism after menopause
- Physiological and biological skin changes in pregnancy
- Anabolic androgenic steroids and carcinogenicity focusing on Leydig cell: a literature review
- Gynecomastia and Premature Thelarche
- Premature Adrenarche
- Eyebrow Loss
- Trichoblastoma of the Breast Detected by Screening Mammography: A Diagnostic Pitfall
- Cytokines
- O-11 DIAGNOSTIC CHALLENGES IN POSTMENOPAUSAL HYPERANDROGENISM: REPORTS OF TWO CASES
- Scalp lesions, in images
- Hair loss in the elderly
- Highlights
- Hirsutism and virilization
- New Drugs for Leukæmia and Tumours
- Methotrexate/tacrolimus/voriconazole
- Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy